Patients' view of pharma slips but some firms gain ground on focused products
This article was originally published in Scrip
Multinational pharmaceutical companies aren't the most disrespected segment of the health care industry; that dubious distinction went to for-profit health insurers in a late 2012 survey of 600 patient groups conducted by the independent UK-based research and consulting firm PatientView.
You may also be interested in...
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.